C12N 2770/36133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/36133 (Use of viral protein as therapeutic agent other than vaccine) appears on 5 US grants and 6 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 6
- Assignees
- 5
- Inventors
- 18
- Latest grant
- 17 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 1 | 1 |
| 2024 | 1 | 0 |
| 2025 | 1 | 0 |
By publication year.
Recent patents
- Alphavirus-based replicons for administration of biotherapeutics17 Jun 2025US 12,331,076 B2Janssen Pharmaceuticals, Inc.
- Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins15 Oct 2024US 12,116,412 B2New York University
- Artificial alphavirus-derived RNA replicon expression systems28 Mar 2023US 11,613,561 B2TIBA Biotech LLC
- Method and composition for modulating immune response1 Jan 2019US 10,166,281 B2VLP Therapeutics, LLC
- DNA antibody constructs and method of using same2 Oct 2018US 10,087,240 B2Inovio Pharmaceuticals, Inc.
- Artificial alphavirus-derived rna replicon expression systems21 Sep 2023US 2023/0295241 A1TIBA Biotech LLC
- Artificial alphavirus-derived rna replicon expression systems22 Sep 2022US 2022/0298210 A1TIBA Biotech LLC
- Induction and Enhancement of Antitumor Immunity Involving Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens and Immune Checkpoint Inhibitors or Proteins3 Dec 2020US 2020/0377598 A1New York University
- Alphavirus-based replicons for administration of biotherapeutics9 Apr 2020US 2020/0109178 A1Janssen Pharmaceuticals, Inc.
- Method and composition for modulating immune response9 Mar 2017US 2017/0065703 A1VLP Therapeutics, LLC
Most cited
By later US patents